原発性胆汁性肝硬変(Primary Biliary Cirrhosis)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Primary Biliary Cirrhosis Overview 7
Therapeutics Development 8
Pipeline Products for Primary Biliary Cirrhosis – Overview 8
Pipeline Products for Primary Biliary Cirrhosis – Comparative Analysis 9
Primary Biliary Cirrhosis – Therapeutics under Development by Companies 10
Primary Biliary Cirrhosis – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Primary Biliary Cirrhosis – Products under Development by Companies 13
Primary Biliary Cirrhosis – Companies Involved in Therapeutics Development 14
AlbireoPharma 14
Dr. Falk Pharma GmbH 15
GlaxoSmithKline plc 16
Intercept Pharmaceuticals, Inc. 17
Johnson & Johnson 18
MediGene AG 19
NGM Biopharmaceuticals, Inc. 20
Shire Plc 21
Virobay Inc. 22
Primary Biliary Cirrhosis – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
A-4250 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
budesonide – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
FFP-104 – Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
GSK-2330672 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NGM-282 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
obeticholic acid – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
RhuDex – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
SHP-625 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ustekinumab – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
VBY-825 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Primary Biliary Cirrhosis – Recent Pipeline Updates 48
Primary Biliary Cirrhosis – Dormant Projects 59
Primary Biliary Cirrhosis – Product Development Milestones 60
Featured News & Press Releases 60
May 28, 2014: Intercept Announces that FDA Grants Fast Track Designation to Obeticholic Acid for the Treatment of Patients with Primary Biliary Cirrhosis 60
Apr 11, 2014: Intercept Announces Preclinical Data Demonstrating OCA’s Potential Role in Preventing Complications of Cirrhosis 60
Apr 04, 2014: Data From Intercept’s Pivotal Phase 3 POISE Trial of Its FXR Agonist Obeticholic Acid to Treat Primary Biliary Cirrhosis and Other Key Obeticholic Acid Data to be Presented at EASL 2014 61
Mar 16, 2014: Intercept Announces Positive Pivotal Phase 3 POISE Trial Results 62
Jan 09, 2014: Intercept Provides 2013 Year-End Update and 2014 Anticipated Milestones 63
Dec 13, 2013: Medigene Granted Additional Patent for RhuDex for the Treatment of Autoimmune Diseases 66
Nov 18, 2013: Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases 66
Oct 29, 2013: Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis 67
Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases 68
May 20, 2013: Intercept Pharma Announces Positive Initial Results From Ongoing Phase IIa Trial In Chronic Bile Acid Diarrhea 68
Appendix 70
Methodology 70
Coverage 70
Secondary Research 70
Primary Research 70
Expert Panel Validation 70
Contact Us 71
Disclaimer 71